Examkin

Soru

Zorluk: ZorPoint at Issue and Point of Agreement

Dr. Sterling: Novel pharmaceuticals for rare terminal conditions should be approved by regulatory agencies only if evaluated through fixed-protocol randomized clinical trials. Adaptive trial designs—which alter randomization ratios or dosing regimens as interim patient outcomes emerge—undermine the experimental blinding and statistical independence necessary to establish definitive causal efficacy.

Dr. Park: While fixed-protocol trials maintain pristine statistical independence, they unethically consign patients to ineffective therapies when early data already demonstrate a clear treatment effect. Moreover, modern Bayesian statistical adjustments adequately compensate for the inferential biases introduced by mid-trial modifications, generating causal evidence sufficiently robust to support regulatory approval.

The dialogue provides the most support for the claim that Dr. Sterling and Dr. Park disagree over which one of the following?

  1. A
    whether fixed-protocol randomized trials are ethically problematic when evaluating treatments for rare terminal conditions
  2. B
    whether mid-trial modifications to trial parameters introduce potential inferential biases into clinical evaluations
  3. whether adaptive trial designs can yield causal evidence sufficiently robust to justify regulatory approval for novel therapeuticsCevap
  4. D
    whether conventional fixed-protocol trials should be entirely eliminated from the regulatory evaluation process
  5. E
    whether establishing definitive causal efficacy is sufficient to guarantee regulatory approval for a novel therapy

Cevap

The dialogue provides the most support for the claim that the speakers disagree over whether adaptive trial designs can yield causal evidence sufficiently robust to justify regulatory approval for novel therapeutics.
The dialogue demonstrates a direct, explicit contradiction regarding whether adaptive clinical trial designs can produce evidence robust enough for regulatory approval. Dr. Sterling asserts that novel pharmaceuticals should be approved only if evaluated through fixed-protocol trials because adaptive designs undermine the statistical independence necessary for definitive causal efficacy. In contrast, Dr. Park claims that modern Bayesian adjustments adequately compensate for these biases, generating causal evidence sufficiently robust to support regulatory approval.

Adım Adım Çözüm

1
Analyze Dr. Sterling's argument and determine their position on the contested issue.
Dr. Sterling argues that novel drugs should be approved only through fixed-protocol trials because adaptive designs compromise the statistical independence required for causal efficacy, concluding that adaptive trials cannot support regulatory approval.
Establishing the first speaker's explicit claims and necessary conditions is essential for applying the point-at-issue test.
2
Analyze Dr. Park's argument and determine their position on the contested issue.
Dr. Park asserts that Bayesian modeling compensates for mid-trial modifications and generates causal evidence sufficiently robust to justify regulatory approval.
Identifying the second speaker's counter-conclusion reveals where direct opposition occurs.
3
Apply the two-speaker agreement/disagreement test across all options to identify the mutually addressed proposition.
Only the proposition regarding whether adaptive designs can produce evidence robust enough for regulatory approval produces an explicit 'No' from Dr. Sterling and an explicit 'Yes' from Dr. Park.
A valid Point at Issue correct answer requires both speakers to take opposing, verifiable stances based solely on the text.

Anahtar Kavram

Identifying explicit points of disagreement through the two-speaker test
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Point at Issue and Point of Agreement

Bu konudan daha fazla soru